Anti-Human HLA-DR, Purified conjugated, clone L243

Anti-Human HLA-DR, Purified conjugated, clone L243
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
E-AB-F1111A.25 25 µg -

7 - 16 Werktage*

14,00 €
E-AB-F1111A.100 100 µg -

7 - 16 Werktage*

44,00 €
 
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD alpha (heavy) chain and... mehr
Produktinformationen "Anti-Human HLA-DR, Purified conjugated, clone L243"
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD alpha (heavy) chain and a 27 kD beta (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Protein function: An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA- DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T- helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:17334368, PubMed:8145819, PubMed:15322540, PubMed:22327072, PubMed:27591323, PubMed:31495665, PubMed:15265931, PubMed:9075930, PubMed:24190431). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self- peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819). [The UniProt Consortium]
Schlagworte: Anti-HLA-DRA, Anti-HLA-DRA1, Anti-MHC class II antigen DRA, Anti-HLA class II histocompatibility antigen, DR alpha chain, Purified Anti-Human HLA-DR Antibody[L243]
Hersteller: Elabscience
Hersteller-Nr: E-AB-F1111A

Eigenschaften

Anwendung: FC, FC (membrane)
Antikörper-Typ: Monoclonal
Klon: L243
Konjugat: No
Wirt: Mouse
Spezies-Reaktivität: human

Handhabung & Sicherheit

Lagerung: +4°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-Human HLA-DR, Purified conjugated, clone L243"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen